Get the Stockscreener App
2.19
0.00%
0.00
After Hours:
2.17
-0.02
-0.91%
Proqr Therapeutics N V stock is traded at $2.19, with a volume of 472.35K.
It is up +0.00% in the last 24 hours and up +14.66% over the past month.
ProQR Therapeutics NV is a biopharmaceutical company. It discovers and develops RNA therapeutics for patients with severe genetic rare diseases such as cystic fibrosis, Leber congenital amaurosis type 10, and dystrophic epidermolysis bullosa. The only reportable segment of the company is the discovery and development of different, RNA-based therapeutics.
See More
Previous Close:
$2.19
Open:
$2.16
24h Volume:
472.35K
Relative Volume:
1.50
Market Cap:
$230.42M
Revenue:
$7.05M
Net Income/Loss:
$-30.43M
P/E Ratio:
-5.7814
EPS:
-0.3788
Net Cash Flow:
$21.84M
1W Performance:
-10.61%
1M Performance:
+14.66%
6M Performance:
+18.38%
1Y Performance:
+18.38%
1-Day Range:
$2.04
$2.215
1-Week Range:
$2.04
$2.48
52-Week Range:
$1.07
$4.62
Proqr Therapeutics N V Stock (PRQR) Company Profile
Compare PRQR with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
PRQR
Proqr Therapeutics N V
|
2.19 | 237.02M | 7.05M | -30.43M | 21.84M | -0.3788 |
|
VRTX
Vertex Pharmaceuticals Inc
|
394.53 | 99.62B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
465.89 | 61.52B | 2.46B | -319.09M | -52.09M | -2.47 |
|
REGN
Regeneron Pharmaceuticals Inc
|
560.00 | 58.91B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ARGX
Argen X Se Adr
|
756.38 | 46.69B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
324.34 | 34.54B | 3.81B | -644.79M | -669.77M | -6.24 |
Proqr Therapeutics N V Stock (PRQR) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-29-25 | Resumed | Cantor Fitzgerald | Overweight |
| Apr-29-25 | Initiated | Evercore ISI | Outperform |
| Mar-10-25 | Upgrade | Citigroup | Neutral → Buy |
| Jan-10-25 | Initiated | Oppenheimer | Outperform |
| Oct-29-24 | Upgrade | Raymond James | Outperform → Strong Buy |
| Nov-08-23 | Upgrade | Chardan Capital Markets | Neutral → Buy |
| Mar-30-23 | Upgrade | JMP Securities | Mkt Perform → Mkt Outperform |
| Dec-22-22 | Upgrade | Cantor Fitzgerald | Neutral → Overweight |
| Feb-14-22 | Downgrade | Citigroup | Buy → Neutral |
| Feb-11-22 | Downgrade | Raymond James | Strong Buy → Mkt Perform |
| Feb-11-22 | Downgrade | Stifel | Buy → Hold |
| Feb-01-22 | Initiated | Raymond James | Strong Buy |
| May-03-21 | Initiated | Stifel | Buy |
| Mar-25-21 | Reiterated | Citigroup | Buy |
| Nov-03-20 | Resumed | Cantor Fitzgerald | Overweight |
| Mar-12-19 | Reiterated | Chardan Capital Markets | Buy |
| Dec-19-18 | Initiated | RBC Capital Mkts | Outperform |
| Nov-15-18 | Initiated | Citigroup | Buy |
| Sep-19-18 | Initiated | Evercore ISI | Outperform |
| Sep-26-17 | Reiterated | JMP Securities | Mkt Outperform |
| Jun-20-16 | Initiated | Chardan Capital Markets | Neutral |
| Oct-15-14 | Initiated | Deutsche Bank | Buy |
| Oct-13-14 | Initiated | H.C. Wainwright | Buy |
View All
Proqr Therapeutics N V Stock (PRQR) Latest News
Forecasting ProQR Therapeutics N.V. price range with options data2025 Market WrapUp & Accurate Trade Setup Notifications - Newser
Can technical indicators confirm ProQR Therapeutics N.V.’s reversalPortfolio Update Report & Verified Momentum Stock Alerts - Newser
Can trapped investors hope for a rebound in ProQR Therapeutics N.V.2025 Big Picture & Advanced Swing Trade Entry Plans - Newser
Visual trend scoring systems applied to ProQR Therapeutics N.V.July 2025 PostEarnings & Weekly Chart Analysis and Guides - Newser
Evaluating ProQR Therapeutics N.V. with trendline analysis2025 Institutional Moves & Risk Controlled Swing Trade Alerts - Newser
ProQR Therapeutics N.V. stock trend outlook and recovery pathJuly 2025 Short Interest & Weekly High Conviction Trade Ideas - Newser
Adage Capital Partners GP L.L.C. Sells 1,500,182 Shares of ProQR Therapeutics N.V. $PRQR - MarketBeat
When is the best time to exit ProQR Therapeutics N.V.July 2025 Review & Technical Analysis for Trade Confirmation - Newser
Using RSI to spot recovery in ProQR Therapeutics N.V.2025 Macro Impact & Free Daily Entry Point Trade Alerts - Newser
Will earnings trigger a reversal in ProQR Therapeutics N.V.Weekly Gains Report & AI Powered Market Trend Analysis - Newser
Measuring ProQR Therapeutics N.V.’s beta against major indicesEarnings Overview Summary & Safe Entry Trade Signal Reports - Newser
What earnings revisions data tells us about ProQR Therapeutics N.V.Market Performance Recap & Weekly Stock Performance Updates - Newser
What technical models suggest about ProQR Therapeutics N.V.’s comebackWeekly Profit Analysis & Breakout Confirmation Alerts - Newser
What institutional flow reveals about ProQR Therapeutics N.V.2025 Momentum Check & Weekly Chart Analysis and Guides - Newser
What Fibonacci levels say about ProQR Therapeutics N.V. reboundQuarterly Earnings Summary & Verified Momentum Stock Ideas - Newser
Is ProQR Therapeutics N.V. stock entering bullish territoryJuly 2025 Sector Moves & Fast Entry and Exit Trade Plans - Newser
How to recover losses in ProQR Therapeutics N.V. stockForecast Cut & Weekly Setup with ROI Potential - Newser
Heatmap analysis for ProQR Therapeutics N.V. and competitorsJuly 2025 Trends & Momentum Based Trading Ideas - Newser
Chart based analysis of ProQR Therapeutics N.V. trendsMarket Trend Report & Safe Capital Growth Tips - Newser
Ranking ProQR Therapeutics N.V. among high performing stocks via toolsJuly 2025 News Drivers & Proven Capital Preservation Tips - Newser
Can ProQR Therapeutics N.V. hit a new high this monthJuly 2025 Highlights & Consistent Growth Equity Picks - Newser
Is ProQR Therapeutics N.V. meeting your algorithmic filter criteriaJuly 2025 Fed Impact & Expert Approved Momentum Trade Ideas - Newser
What high frequency data says about ProQR Therapeutics N.V.2025 Key Highlights & Daily Profit Maximizing Trade Tips - Newser
Is ProQR Therapeutics N.V. building a consolidation baseJuly 2025 WrapUp & Free Long-Term Investment Growth Plans - Newser
statistical indicators supporting proqr therapeutics n.v.’s strengthJuly 2025 PreEarnings & Real-Time Buy Zone Alerts - Newser
Momentum divergence signals in ProQR Therapeutics N.V. chartEarnings Risk Summary & Technical Buy Zone Confirmation - Newser
Analysis Recap: Is ProQR Therapeutics N.V. stock a good dividend stock2025 Investor Takeaways & Precise Trade Entry Recommendations - Lancaster City Council
Will ProQR Therapeutics N.V. price bounce be sustainableMarket Volume Summary & Weekly Momentum Stock Picks - Newser
Will ProQR Therapeutics N.V. see short term momentumEarnings Performance Report & Free Real-Time Market Sentiment Alerts - Newser
American Century Companies Inc. Decreases Stock Position in ProQR Therapeutics N.V. $PRQR - Defense World
ProQR Therapeutics N.V. Forms Bullish Flag — Upside AheadJobs Report & Daily Volume Surge Trade Alerts - beatles.ru
How hedge fund analytics apply to ProQR Therapeutics N.V. stockJuly 2025 Catalysts & Scalable Portfolio Growth Ideas - Newser
What data driven models say about ProQR Therapeutics N.V.’s futureWeekly Stock Report & Technical Analysis for Trade Confirmation - Newser
Proqr Therapeutics N V Stock (PRQR) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.93%
0.10%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):